Amgen Inc at Morgan Stanley Global Healthcare Conference Transcript
All right. Thanks for joining us, everybody. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see Morgan Stanley's research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Very pleased to be hosting Amgen this afternoon. I'm going to turn it over to the company's new CFO, Thomas Dietrich, who's going to make some opening remarks and then we'll launch into Q&A with the rest of the team. But thank you everyone for being here.
Karen, thank you so much and it's really good to be here.
Before we get into Q&A, I'd like to take some time to introduce myself and share a few thoughts on how we see the business today. As many of this is my second chapter at Amgen.
I spent
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
